Viatris Inc. will present six abstracts on its investigational low‑dose estrogen combined hormonal contraceptive patch at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., scheduled for May 1‑3, 2026.
The abstracts cover the Phase 3 study (NCT05139121) and include data on contraceptive efficacy, safety, adhesion performance under normal and extreme conditions, pharmacokinetics, and cycle‑control. The trial demonstrated favorable efficacy and safety outcomes and strong adhesion performance that the company claims is best‑in‑class. The patch delivers a lower estrogen dose—17.5 µg of ethinyl estradiol per day versus 35 µg in the current Xulane product—while maintaining contraceptive effectiveness for women with a BMI below 30 kg/m².
Viatris has received FDA acceptance for a New Drug Application under the 505(b)(2) pathway, with a target action date (PDUFA) of July 30 2026. The 505(b)(2) pathway allows the agency to rely on data from the already approved Xulane product, potentially streamlining the review of the new low‑dose patch.
The weekly patch represents a lifecycle extension of Viatris’s existing transdermal platform built around Xulane. If approved, the product could open a contraceptive market worth more than $2 billion and provide a higher‑margin, differentiated offering within the company’s portfolio.
Viatris’s recent financial performance underscores its capacity to support new product development. Q4 2025 revenues reached $3.7 billion, and full‑year 2025 revenues totaled $14.3 billion. In Q1 2025, total revenues were $3.3 billion, down 11 % year‑over‑year, largely due to the “Indore Impact.” The company’s strong revenue base supports continued investment in its pipeline.
In a Q4 2025 earnings release, CEO Scott A. Smith said, “2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength.” Chief R&D Officer Philippe Martin added, “We are pleased with the profile our investigational XULANE LO low dose patch demonstrated in this Phase 3 study. The data underscores our confidence in the potential of XULANE LO to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best‑in‑class adhesion performance.”
The contraceptive market is highly competitive, with oral pills, patches, rings, and other methods available. Viatris’s low‑estrogen patch differentiates itself through a reduced estrogen dose and strong adhesion, addressing a segment of women who may be sensitive to higher estrogen levels or who prefer a non‑oral option. The company’s existing Xulane platform provides a proven safety and efficacy foundation, while the new patch’s weekly dosing schedule offers convenience.
The presentation of Phase 3 data at the ACOG meeting is a key milestone that will inform the FDA review process and generate clinical community interest. Successful regulatory approval could accelerate Viatris’s entry into a sizable market and enhance its portfolio with a higher‑margin product.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.